Alzheimer's Disease Research Center

阿尔茨海默病研究中心

基本信息

批准号：
10622633
负责人：
DAVID M. HOLTZMAN
金额：
$ 307.63万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-15 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10622633
关键词：
Acceleration Address Age Alzheimer disease prevention Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Amyloid Area Autopsy Basic Science Behavioral Biological Markers Biopsy Blood Brain Cerebrospinal Fluid Clinical Clinical Sciences Cognitive Collaborations Communities Consent DNA Data Data Set Dementia Dermal Development Diagnosis Disease Ensure Environment Etiology Faculty Fibroblasts Financial Support Fostering Functional Magnetic Resonance Imaging Funding Genetic Goals Grant Image International Knowledge Memory Molecular Profiling Multicenter Studies National Institute on Aging Participant Pathogenesis Pathologic Performance Persons Plasma Population Positron-Emission Tomography Prevention trial Productivity Psychometrics Research Research Personnel Research Project Grants Resources Rest Scientist Services Skin Students Symptoms Thinking Tissues Training Universities Washington Work brain magnetic resonance imaging brain tissue career development clinical center clinical phenotype cohort data management design disorder prevention education research effective therapy induced pluripotent stem cell innovation instrument metropolitan mild cognitive impairment molecular marker multidisciplinary multimodality neuropathology normal aging outreach pre-clinical prevent programs racial diversity recruit repository skills statistics student training tau Proteins transmission process

项目摘要

Overall Project Summary The Washington University Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) initiates, fosters, and supports the performance of innovative, cutting-edge research on Alzheimer disease (AD) and related dementias (ADRD) with regard to the etiology, pathogenesis, diagnosis, treatment, and prevention of disease. The Knight ADRC's efforts thus fully align with the primary goal of the National Alzheimer's Project Act of 2011, “to prevent and effectively treat ADRD by 2025”. We provide well- characterized research participants (persons with symptomatic AD and age-matched controls), their clinical, psychometric, and imaging data, and their tissue (DNA, CSF, plasma, dermal fibroblasts, iPSCs, brain tissue) to research projects. We also provide intellectual and financial support to scientists at Washington University, at other Alzheimer Disease Centers, and the research community nationally and internationally and engage in formal and informal collaborations, including multi-disciplinary/multi-Center studies and the initiatives sponsored by the National Institute on Aging, the National Alzheimer Coordinating Center, and the National Centralize Repository for ADRD. Historically, our Center has focused on the earliest stages of dementia to identify the initial clinical and pathologic changes that distinguish AD from normal aging. Our approach is balanced between clinical and basic science domains with emphasis on interdisciplinary efforts. We will continue our training of students, fellows and junior faculty in clinical and basic science research skills. We will continue to engage in outreach activities to transfer information on ADRD to lay and professional audiences. We are committed to assuring that our research cohort reflects the racial diversity of the greater metropolitan St. Louis area and will continue activities that promote the inclusion of these populations in research. This renewal application includes seven Cores, plus the new Research Education Component (REC): A: Administration, B: Clinical, C: Data Management and Statistics, D: Neuropathology, E: Outreach, Recruitment, and Engagement, F: Biomarker, G: Genetics and High Throughput -Omics.

总体项目摘要华盛顿大学查尔斯·F·和乔安妮·奈特·阿尔茨海默氏病研究中心（骑士） ADRC）启动，养育和支持有关阿尔茨海默氏症创新的尖端研究的表现关于病因，发病机理，诊断，治疗，疾病（AD）和相关痴呆症（ADRD）和预防疾病。因此，骑士ADRC的努力与国家的主要目标完全保持一致阿尔茨海默氏症2011年的项目法案，“到2025年，预防和有效地对待ADRD”。我们提供良好的特征是研究参与者（有症状广告和年龄匹配的对照者），他们的临床，心理测量和成像数据及其组织（DNA，CSF，血浆，皮肤成纤维细胞，IPSC，脑组织）研究项目。我们还向华盛顿大学的科学家提供智力和财政支持，在其他阿尔茨海默氏病中心，以及在国内和国际上的研究界，并参与正式和非正式的合作，包括多学科/多中心研究和计划由国家老化研究所，国家阿尔茨海默氏症协调中心和国家的赞助集中存储库。从历史上看，我们的中心一直专注于痴呆症的最早阶段确定将AD与正常衰老区分开的初始临床和病理变化。我们的方法是在临床和基础科学领域之间保持平衡，重点是跨学科工作。我们将继续我们在临床和基础科学研究技能方面对学生，研究员和初级教师进行培训。我们将继续从事外展活动，以将有关ADRD的信息转移到外行和专业受众。我们致力于确保我们的研究队列反映了更大的大都市的种族多样性圣路易斯地区，并将继续活动，以促进这些人群的研究。此续签应用包括七个核心，以及新的研究教育部分（REC）： A：管理，B：临床，C：数据管理和统计数据，D：神经病理学，E：外展，招聘和参与，F：生物标志物，G：遗传学和高吞吐量 - 组。

项目成果

期刊论文数量（8）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Sons and parental cognition in mid-life and older adulthood.

DOI：
10.1016/j.jpsychires.2022.10.026
发表时间：
2022-12
期刊：
JOURNAL OF PSYCHIATRIC RESEARCH
影响因子：
4.8
作者：
Wolfova, Katrin;Wu, Di;Weiss, Jordan;Cermakova, Pavla;Kohler, Hans-Peter;Skirbekk, Vegard Fykse;Stern, Yaakov;Gemmill, Alison;Tom, Sarah E.
通讯作者：
Tom, Sarah E.

Vascularized Brain Assembloids With Enhanced Cellular Complexity Provide Insights Into the Cellular Deficits of Tauopathy.

细胞复杂性增强的血管化大脑组合体为了解 Tau 蛋白病的细胞缺陷提供了见解。

DOI：
10.1093/stmcls/sxad086
发表时间：
2024
期刊：
Stem cells (Dayton, Ohio)
影响因子：
0
作者：
Sun,Xiaohuan;Kofman,Simeon;Ogbolu,VictorC;Karch,CelesteM;Ibric,Larisa;Qiang,Liang
通讯作者：
Qiang,Liang

DANSR: A Tool for the Detection of Annotated and Novel Small RNAs.

DOI：
10.3390/ncrna8010009
发表时间：
2022-01-13
期刊：
Non-coding RNA
影响因子：
4.3
作者：
Zhang J;Eteleeb AM;Rozycki EB;Inkman MJ;Ly A;Scharf RE;Jayachandran K;Krasnick BA;Mazur T;White NM;Fields RC;Maher CA
通讯作者：
Maher CA

Weakly activated core neuroinflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer's disease.